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Invasive lobular carcinoma of the breast has better
short- and long-term survival than invasive ductal
carcinoma
S Toikkanen', L Pylkkanen2and H Joensuu3
Departments of 'Pathology and 2Oncology, University Central Hospital of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland; 3Department of Oncology,
University Central Hospital of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland
Summary The outcome and prognostic factors of 217 women with invasive lobular carcinoma (ILC) and those of 1121 women with invasive
ductal carcinoma (IDC) of the breast were compared. The patients were followed up for 10-43 years. Women with ILC had axillary nodal
metastases less frequently than those with IDC (43% vs 53%, P= 0.02), although there was no difference in the primary tumour size between
the groups. ILCs were more frequently of low grade, had lower mitotic counts and had less tumour necrosis. Furthermore, ILCs had lower S-
phase fractions and were more often DNA diploid in flow cytometric analysis than IDCs (P < 0.0001 for all comparisons). The 5- and 30-year
corrected survival rates of women with ILC were 78% and 50%, respectively, compared with 63% and 37% for women with IDC (P= 0.001).
Small pTl NOMO ILCs (n = 41) had 100% 10-year and 83% 20-year corrected survival rates. In a multivariate analysis, a large primary tumour
size, the presence of axillary nodal metastases, a high mitotic count and the presence of tumour necrosis all had an independent prognostic
value in ILC. We conclude that ILC is associated with better survival than IDC.
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Carcinoma of the breast is a histologically heterogeneous disease.
Using their light microscopical appearance, the invasive forms are
usually divided into three main groups: infiltrating ductal carci-
nomas (IDC), infiltrating lobular carcinomas (ILC) and other
infiltrating carcinomas (special histological types) (ISC). IDCs
constitute 70-85% of all invasive breast carcinomas, ILCs 5-20%
and ISCs about 10% (Correa and Johnson, 1978; Martinez and
Azzopardi, 1979). There is general agreement that patients with
ISC have significantly better prognosis than those with IDC or
ILC, but there is still controversy as to whether the prognoses of
IDC and ILC differ (Howell and Harris, 1985; DiCostanzo et al,
1990; Sastre-Garau et al, 1996). The studies performed to solve
this issue have mostly been based on a small number of patients,
and relatively few reports including more than 100 cases have been
published so far (Dixon et al, 1982; DiCostanzo et al, 1990; du
Toit et al, 1991; Silverstein et al, 1994). Moreover, only a few
reports are based on a well-defined cohort, and there is little data
available comparing long-term survival of patients with ILC with
that ofpatients with IDC (Sastre-Garau et al, 1996).
Here, we report a series consisting of 1338 female patients with
a biopsy-verified IDC or ILC, diagnosed in a well-defined urban
population. All cases have been examined and reclassified
according to uniform criteria for this study, and all patients have
been followed-up for a minimum of 10 years after the diagnosis or
until death.
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MATERIALS AND METHODS
Patient identification and follow-up
In order to identify all patients diagnosed with invasive breast
cancer in the city ofTurku, located in South-Western Finland, the
hospital records of the two hospitals treating breast cancer in the
area, the Turku University Central Hospital and the City Hospital
of Turku, were examined. In addition, we searched the data
obtained from the Finnish Cancer Registry, founded in 1952. All
hospitals, practising physicians and pathological laboratories are
requested to report to the Finnish Cancer Registry all cases of
cancer that come to their attention. In addition, all death certifi-
cates in which cancer is mentioned are transferred from the files of
the Central Statistical Office of Finland to the Cancer Registry
each year. After identifying the patients from these sources, we
reviewed the hospital and autopsy case records and examined the
histological and autopsy slides. We could identify and confirm the
diagnosis of invasive breast cancer in 1495 female patients during
the time period from 1945 to 1984. Based on the data obtained
from the Finnish Cancer Registry and other data, we estimate that
this is 94% of all cases diagnosed with breast cancer in the city
during the time period.
The majority of the 1495 patients studied had IDC (n = 1121,
75.0%); 217 (14.5%) had ILC and 157 (10.5%) had ISC, including
tubular, medullary, pure mucinous, papillary and cribriform carci-
nomas. The 1338 women with IDC or ILC form the basis of the
present study. Of the 1033 patients who died during the follow-up
(77% of the 1338 cases), 672 (65%) died ofbreast cancer, 66 (6%)
died of a malignancy other than breast cancer, 290 (28%) died of
other diseases and, in five cases (0.5%) the cause of death could
not be determined. Twenty-three per cent (n = 305) of the 1338
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Table 1 Treatment of patients with invasive ductal or lobular carcinoma of
the breast
Treatment Ductal cancer Lobular cancer
(n = 1121) (n = 217)
n(%) n(%)
Surgery
Mastectomy and axillary evacuation 976 (87) 184 (85)
Mastectomy 116 (10) 25 (12)
Lumpectomy 18 (2) 4 (2)
Biopsy only 6 (1) 4 (2)
Data missing (n = 5)
Post-operative radiotherapy
Not given 308 (28) 55 (25)
Given 810 (72) 161 (75)
Data missing (n = 4)
Adjuvant therapy
None 1019 (91) 202 (93)
Tamoxifen 28 (2) 6 (3)
Ovarian ablation 54 (5) 6 (3)
Cytotoxic/other 20 (2) 3 (1)
patients were still alive, and each of these patients have been
followed up forbetween 120 and 517 months (from 10 to 43 years;
median 17 years).
Therapy
The majority (87%) of the patients were treated with mastectomy
and axillary nodal evacuation, and most (73%) received post-
operative radiotherapy to the locoregional area. Only 8.7% had
been treated with adjuvant therapy, which usually consisted of
ovarian ablation (4.5%). There was no significant difference
between the therapy given to patients with IDC and that given to
patients with ILC (Table 1).
Histology
All original histological slides were re-typed and re-graded
without knowledge of survival data and, if necessary, new haema-
toxylin and eosin (H-E)-stained slides were prepared. Histological
typing was performed according to the WHO classification
(WHO, 1981). ILCs were categorized as either 'classical'
(n = 157) or 'variant' forms (n = 60) using the criteria published
previously (Fechner, 1975; Fisher et al, 1977; Martinez and
Azzopardi, 1979). Grading of the IDCs was performed according
to the WHO classification, and the grading ofILCs was performed
by evaluating the degree of nuclear pleomorphism (WHO, 1981).
The number of mitoses per a high-power field (Leizt Orthoplan
microscope, x 400 magnification) was counted as an average
of ten fields. The amount of tumour necrosis was estimated on
the scale 'none', 'slight', 'moderate' or 'severe' (from 0 to 3). The
primary tumour size, the axillary nodal status and the presence
of distant metastases were recorded using the UICC TNM
classification (1987).
DNA flow cytometry
DNA ploidy of 637 carcinomas had been determined by flow
cytometry as described previously in conjunction with another
study of paraffin-embedded tissue (Toikkanen et al, 1989). The
Table 2 Comparison of nine clinicopathological factors in invasive ductal
and lobular carcinoma
Factor Ductal Lobular P-value
(n = 1122) (n = 217)
n(%) n(%)
Tumour size (cm)
< 2 (pTl) 307 (27) 65 (30)
2-5 (pT2) 510 (47) 107 (50)
> 5 (pT3-4) 279 (26) 42 (20) 0.19
Axillary nodes
Negative (pNO) 460 (47) 102 (57)
Positive (pN+) 509 (53) 78 (43) 0.02
Distant metastases at
diagnosis
No 1040 (93) 199 (92)
Yes 77 (7) 18 (8) 0.46
Grade
228 (20) 74 (34)
11 486 (44) 117 (54)
III 407 (36) 26 (12) < 0.0001
Mitoses/HPFa
<2 381 (34) 147 (68)
2 or 3 465 (41) 58 (27)
> 3 275 (25) 11 (5) < 0.0001
Necrosis
No 743 (66) 201 (93)
Slight 201 (18) 12 (6)
Moderate to severe 177 (16) 4 (1) < 0.0001
DNA ploidyb
Diploid 140 (27) 62 (54)
Non-diploid 383 (73) 52 (46) < 0.0001
S-phase fractionc
Median (%) 9.0 4.0
Range (%) 1.0-38.0 1.0-36.0 <0.0001
Age at diagnosis (years)
Median 59 60
Range 24-93 25-97 0.69
aHPF, high-power field. bNumber of patients with data available, 637.
cNumber of patients with data available, 464.
tumours were classified as DNA diploid (one unimodal GO/GI
peak) or DNA non-diploid (presence of two or more GJG1 peaks,
includes DNA tetraploid cases). The S-phase fraction (SPF) was
calculated using the rectangular method. SPF could be calculated
for 464 cases; for the remainder, it was not calculated because of
excessive cell debris in the DNA histogram or the presence of
overlapping DNA stemlines.
Statistical methods
Statistical analyses were performed with the BMDP computer
program (BMDP Statistical Software, Department of
Biomathematics, University of California, Los Angeles, CA,
USA). Frequency tables were analysed with the chi-square test.
The age and SPF distributions of different patient groups were
compared using the Mann-Whitney U-test. The cumulative
survival was estimated with the product-limit method, and compar-
ison ofthe cumulative survival rate between groups was performed
using the log-rank and generalized Wilcoxon tests. Both overall
(crude) survival rates and survival rates corrected for intercurrent
deaths were calculated. When calculating the corrected survival
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Figure 1 Survival corrected for intercurrent deaths in invasive lobular and
invasive ductal breast cancer. The 5-, 10-, 20- and 30-year survival figures
are given
Table 3 Survival of patients with invasive lobular or ductal carcinoma of the
breast
Follow-up Lobular Ductal P-value
carcinoma carcinoma log-rank/generalized
(%) (%) Wilcoxon
Overall survival
5 year 71 57
10 year 47 41
20 year 29 23
30 year 16 11 0.01/0.001
Survival corrected for
intercurrent deaths
5 year 78 63
10year 62 52
20 year 51 41
30 year 50 37 0.001/0.0004
rates, patients who had died from causes other than breast cancer
according to autopsy or clinical evidence were withdrawn from the
analysis at the date of death. In previous analyses using the same
data, we have compared the corrected survival rate obtained by
identifying the intercurrent deaths based on clinical evidence and
the relative survival obtained by dividing the overall survival ofthe
cohort by the expected survival in the age- and sex-matched
general population; we found both methods to result in an almost
identical survival curve, suggesting that there is no major misclas-
sification ofbreast cancer deaths as intercurrent deaths in the series
(Joensuu and Toikkanen, 1995). The relative importance of prog-
nostic factors was analysed with Cox's proportional hazard model
(BMDP 2L). All P-values are two-tailed.
RESULTS
Comparison of clinicopathological factors
During the period 1945 to 1984 the relative frequencies ofILC and
IDC remained similar. In 1945-59, 1960-69, 1970-79 and
1980-84, the ratio ofILC to IDC was 0.20 (38:191), 0.16 (39:237),
0.18 (78:437) and 0.24 (62:256) respectively (P = 0.28).
Clinicopathological factors between IDC and ILC are compared
in Table 2. ILCs were more frequently of low grade, had lower
mitotic counts, were less often necrotic and more often DNA
diploid, and had lower SPFs than IDCs (P<0.0001 for each
comparison). ILCs more rarely had axillary nodal metastases than
IDCs (P = 0.02), although there was no significant difference in
the primary tumour size between the groups (P = 0.19).
There was no difference in the age distribution (P = 0.69) ofthe
patients nor in the frequency of distant metastases at diagnosis
between the groups (P = 0.46) (Table 2). Similarly, there was no
significant difference in the frequency for the known presence of
cancer in first-degree female relatives (7% vs 8%, P = 0.63), for
the presence of inflammatory carcinoma (1% vs 2%, P = 0.65) or
for skin ulceration at presentation (4% vs 1%, P = 0.08) However,
asignificantly higherproportion ofwomen with ILC (11%, n = 26)
developed cancer in the contralateral breast during follow-up
compared with those with IDC (6%, n = 71) (P = 0.006). Two
patients (0.9%) with ILC and five (0.4%) with IDC had synchro-
nous bilateral breast cancer at presentation, and 24 (11.1%)
women with ILC and 66 (5.9%) with IDC developed metachro-
nous contralateral breast cancer during the follow-up.
Univariate survival analyses in ILC
Patients with ILC had a more favourable overall and corrected
survival rate than patients with IDC (P = 0.001 by the log-rank test
and P < 0.0004 by the generalized Wilcoxon test, n = 1241) (Table
3 and Figure 1). The 5- and 30-year corrected survival rates for
women with ILC were 78% and 50%, respectively, compared with
63% and 37% among women with IDC. The difference in survival
was already evident after the first 5 years of follow-up (Figure 1
and Table 3).
If the cases with bilateral cancer were excluded from the
analysis, the difference between the survival rates remained similar
(P = 0.002/0.0005). Similarly, if the patients who had received
adjuvant therapy (n = 117) were excluded from the survival
analysis, there was still a survival difference of the same order of
magnitude in favour of women with ILC (n = 1221,
P = 0.004/0.001).
Both overall survival (P = 0.02/0.01) and survival corrected for
intercurrent deaths (P = 0.009/0.007) of patients with ILC were
significantly better than those of patients with grade II IDC
but were worse than survival of patients with grade I IDC
(P = 0.01/0.002 for overall and P < 0.001/< 0.001 for corrected
survival). However, there was no significant difference either in
overall survival (P = 0.34/0.28) or survival corrected for intercur-
rent deaths (P = 0.21/0.16) between IDC and ILC if only patients
with axillary node-negative disease were entered into a survival
analysis. The 41 patients with unilateral small pTlNOMO ILC had
an excellent outcome with a 100% 10-year and 83% 20-year
survival rate corrected for intercurrent deaths.
There was no significant difference in survival between women
with the classical histological type ofILC (n = 157) and those with
the variant histological type ofILC (n = 60); the 20-year corrected
survival rates were 56% and 41% respectively (P = 0.11/0.15).
The eight clinicopathological factors that were significantly asso-
ciated with survival in operable unilateral ILC treated with mastec-
tomy and axillary nodal evacuation with or without radiotherapy are
listed in Table 4. Patients who had received adjuvant therapy
(n = 15) or who were treated with mastectomy or lumpectomy only
(n = 33), patients withbilateral cancer(n = 11) andthose withdistant
metastases at diagnosis (n = 18) were excluded, leaving 140 patients
in the analyses. A small primary tumour size (P < 0.0001), lack of
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Table 4 Survival corrected for intercurrent deaths by eight clinicopathological factors in unilateral invasive lobular carcinoma treated with
curative intent (mastectomy and axillary nodal evacuation + locoregional radiotherapy) but without adjuvant systemic therapy (n = 140)
Factor n Survival P-value
log-rank/generalized
5 year 10 year 20 year Wilcoxon
(%) (%) (%)
Tumour size (cm)
< 2 (pTl) 48 98 96 75
2.1-5 (pT2) 67 84 63 60 < 0.0001/
> 5 (pT3-4) 23 52 26 20 < 0.0001
Axillary nodes
Negative (pNO) 90 93 82 73 < 0.0001/
Positive (pN+) 49 66 41 30 < 0.0001
Necrosis
None 129 87 72 62 0.0001/
Slight to severe 10 32 16 16 0.0001
Mitoses/HPFa
< 2 100 90 76 63
2 or 3 31 77 56 56 0.0002/
> 3 8 30 15 15 < 0.0001
Grade
53 94 78 63
11 71 85 69 62 0.001/
III 16 42 35 35 < 0.0001
S-phase fractionb
<4% (median) 31 93 77 64 0.005/
* 4% 25 64 36 28 0.003
DNA ploidyb
Diploid 41 85 68 62 0.13/
Non-diploid 28 78 52 42 0.16
Age at diagnosis (years)
.60 71 90 68 60 0.91/
> 60 69 77 70 53 0.69
aHPF, high-power field. bS-phase fraction was available in 56 and DNA ploidy in 69 cases.
axillary nodal metastases (P < 0.0001), absence of tumour necrosis
(P < 0.0001), a low mitotic count (P < 0.0001), low histological
grade (P =0.001) and alowerthan the median SPF (P =0.005) were
associated with favourable outcome, whereas age at diagnosis
(P = 0.91) and DNA ploidy (P = 0.13) were not.
When similar univariate survival analyses were carried out
among patients with node-negative ILC treated with mastectomy
and axillary evacuation but without adjuvanttherapy (n = 90, Table
5), a low mitotic count (P < 0.0002), a small primary tumour size
(P < 0.0008) and the lack of tumour necrosis (P = 0.009) were
significantly associated with favourable prognosis. It is worth
noting that none of the 14 patients with a SPF of4% or less died,
whereas the 20-year survival rate of the 15 patients with a SPF
> 4% was only 46%. Despite the small number of patients in this
analysis, the result was very significant (P = 0.008). Neither DNA
ploidy (P = 0.51) nor age younger than the median at diagnosis
(< 61 years, P = 0.14) were significantly associated with survival.
Multivariate survival analyses
When the factors listed in Table 4, except for the SPF, DNA ploidy
and age at diagnosis, were entered in a multivariate analysis for
patients with unilateral ILC given curative treatment without adju-
vant therapy (n = 140), the primary tumour size and the axillary
nodal status turned out to be the most important independent prog-
nostic factors (P < 0.001 for both, Table 6). The extent of tumour
necrosis and the mitotic count also had independent prognostic
value, whereas histological grade did not. For axillary node-
negative ILC (n = 90), the primary tumour size was the most
important independent factor (P = 0.001, Table 6).
In order to find out whether lobular histology is an independent
prognostic variable among patients with unilateral IDC or ILC
with no distant metastases at presentation (MO) and given curative
treatment (n = 1124), we entered the histological type (ductal vs
lobular) togetherwith the primary tumour size (pT4 orpT3 vs pT2
vs pTl), axillary nodal status (pN+ vs pNO), histological grade
(grade III vs grade II vs grade I), mitotic count (> 3 vs 2 or 3 vs
< 2 mitoses perhigh-powerfield), the presence oftumour necrosis
(slight to severe vs no necrosis) and age at diagnosis using the
median age as the cut-off level (< 59 vs > 59 years) into a Cox's
multivariate analysis. The results showed that the histological type
(P = 0.98), tumour necrosis (P = 0.97) and age at diagnosis
(P = 0.16) did not have independent prognostic value, whereas the
axillary nodal status (P < 0.001; RR 2.8, confidence intervals (CI)
2.3-3.4), the primary tumour size (P < 0.001; RR 1.9, CI 1.7-2.2),
histological grade (P < 0.001; RR 1.5, CI 1.2-1.8) and the mitotic
count (P = 0.03; RR 1.2, CI 1.02-1.5) were independent prog-
nostic factors.
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Table 5 Survival corrected for intercurrent deaths by seven clinicopathological factors in unilateral node-negative (pNO) invasive lobular
carcinoma treated with curative intent (mastectomy and axillary nodal evacuation ± locoregional radiotherapy) but without adjuvant therapy
(n = 90)
Factor n Survival P-value
log-rank/generalized
5 year 10 year 20 year Wilcoxon
(%) (%) (%)
Mitoses/HPFa
<2 66 97 87 74
2 or 3 18 94 77 77 0.0002/
> 3 5 27 27 27 < 0.0001
Tumour size (cm)
< 2 (pTl) 41 100 100 83
2.1-5 (pT2) 39 87 72 72 0.0008/
>5(pT3-4) 10 90 50 33 0.0005
S-phase fractionb
< 4% 14 100 100 100 0.008/
> 4% 15 80 57 46 0.01
Necrosis
None 85 95 83 74 0.009/
Slight to severe 4 38 38 38 0.0005
Age at diagnosis (years)
< 61 44 100 88 79 0.14/
> 61 46 86 76 57 0.09
Grade
37 97 86 77
11 44 95 82 71 0.39/
III 9 63 63 63 0.12
DNA ploidyb
Diploid 24 91 81 81 0.51/
Non-diploid 14 93 76 65 0.66
aHPF, high-power field. bS-phase fraction was available in 29 and DNA ploidy in 38 cases.
DISCUSSION
In the present series the proportion of ILC was 14.5%. In
previously reported series, there is considerable variation in the
frequency ofILC ranging from 0.6% to 20% (Correa and Johnson,
1978; Martinez and Azzopardi, 1979). Such variation is most
probably due to different histopathological criteria for ILC rather
than to real variations in the incidence. According to Azzopardi
(1983), the expected proportion of ILC is about 12-14% of all
breast cancers and, if less than 8% is found, the diagnostic criteria
may need to be revised (Azzopardi, 1983).
The definition of ILC has been focused and finely tuned several
times since the original description of ILC by Foote and Stewart
(1941, 1946). According to their definition, the cells of ILC grow in
thread-like strands, rather loosely dispersed throughout a fibrous
matrix. Circumferential growth around non-neoplastic ducts (the
targetoid pattern) and arrangement in a linear pattern (Indian files) are
typical features for ILC. Individual cells are small or medium sized
and commonly elliptical in shape. They areratheruniform andexhibit
relatively little cytological irregularity (Foote and Stewart, 1946).
In the 1950s and 1960s, it was thought that ILC is almost always
accompanied by in situ areas (lobular carcinoma in situ, LCIS;
Newman, 1966), but Fechner (1972) stated that the diagnosis of
ILC can be made in the absence ofLCIS, provided that the growth
pattern is otherwise typical for ILC. At present, it is generally
accepted that LCIS is present in 60-70% of all ILC cases and that
the presence of LCIS is by no means mandatory for the correct
diagnosis ofILC (Dixon et al, 1982).
Fechner (1972) described ductal epithelial involvement, i.e.
carcinoma cells may cause thickening ofthe duct lining or grow in
a pagetoid manner. Solid fillings of ducts may occur, and typical
ILC may quite frequently exist in combination with other types of
invasive carcinoma (Fisher et al, 1975). Moreover, several variants
ofILC that differ from the classical form have been described: the
solid or confluent variant (Fechner, 1975), the tubulolobular
variant (Fisher et al, 1977) and trabecular and alveolar variants
(Martinez and Azzopardi 1979). The variant patterns usually exist
only in a modest proportion ofthe whole tumour volume, and they
are rarely the dominant feature (Dixon et al, 1982).
At the cellular level, there are also variations distinct from the
classical bland cell type. These include the signet-ring cell type
(Steinbrecher and Silverberg, 1976), histiocytoid or apocrine cell
type (Eusebi et al, 1984) and pleomorphic cell type (Azzopardi,
1983). True ILC and ductal carcinoma in situ (DCIS) may also
coexist in the same histological section, as may IDC and LCIS
(Dixon et al, 1982). Such combinations may be confusing and
hamper the correct histological typing ofbreast carcinomas. There
is currently a consensus that there is no single criterion that is
uniformly pathognomonic for ILC, and the precise histological
definition of ILC has been claimed to remain elusive (DiCostanzo
et al, 1990). Indeed, about 3-4% of breast carcinomas cannot be
classified with certainty (Azzopardi, 1979).
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Table 6 The results of multivariate analyses in unilateral invasive lobular carcinoma treated with curative intent (mastectomy and axillary nodal evacuation +
locoregional radiotherapy) but without adjuvant therapy
Factor P-value 1B Standard Relative
error of risk (95% Cl)
All cases (n = 140)
Tumour size < 0.001 1.02 0.24 2.8 (1.7-4.5)
(pT3-4 vs pT2 vs pTl)
Axillary nodes <0.001 1.37 0.31 3.9 (2.2-7.2)
(pN+ vs pNO)
Mitoses/HPFa 0.004 0.58 0.22 1.8 (1.2-2.7)
(>3 vs 2 or 3 vs < 2)
Necrosis 0.02 1.15 0.43 3.1 (1.4-7.2)
(slight to severe vs none)
Histological grade 0.90 (NS)b
(3 vs 2 vs 1)
Patients with node-negative cancer (n = 90)
Tumour size 0.001 1.10 0.34 3.0 (1.5-5.8)
(pT3-4 vs pT2 vs pTl)
Mitoses/HPFa 0.08 0.70 0.35 2.0 (1.0-4.0)
(>3 vs 2 or 3 vs<2)
Necrosis 0.34 (NS)b
(slight to severe vs none)
aHPF, high-power field. bNS, not significant.
There are only few series on ILC that contain survival data from
more than 100 patients, and follow-up ofthe patients in these series
has been for fewer than 10 years except for a small proportion of
patients. In line with the present findings, Dixon et al (1985) found
in their series of 105 patients that those with ILC have better
outcome than those with IDC. A similar conclusion was reached by
Du Toit et al (1991) and Silverstein et al (1994) in their studies
consisting of 171 and 161 patients respectively. DiCostanzo et al
(1990) compared survival of 230 patients with ILC with stage-
matched patients with IDC. Patients with stage I ILC were found to
have significantly better survival than those with stage I IDC, but
this difference disappeared when the comparison was carried out in
stage II cancer. There was no difference in overall survival between
ILC and other invasive carcinomas ofthe breast in the largest series
of ILC published so far, consisting of726 patients (Sastre-Garau et
al, 1996), but follow-up in this series was relatively short with only
25 patients followed up for 10 years.
In the present series, ILCs were significantly more often of low
histological grade, had lower mitotic counts, were less often
necrotic and more often DNA diploid and had a lower SPF than
IDCs. Furthermore, ILCs had axillary nodal metastases signifi-
cantly less often than IDCs. The differences in the distribution of
these important prognostic variables are compatible with the more
favourable outcome of ILC compared with IDC. ILCs have also.
been found to be associated with a low histological grade by others
(Silverstein et al, 1994; Sastre-Garau et al, 1996), but reports on
the frequency of axillary nodal involvement are contradictory
(Silverstein et al, 1994; Sastre-Garau et al, 1996). ILCs have been
reported to express more often oestrogen and progesterone recep-
tors (Helin et al, 1989; Sastre-Garau et al, 1996) and less often
erbB-2 and p53 oncogenes (Toikkanen et al, 1992; Rosen et al,
1995) than IDCs, and their bcl-2 expression has been reported to
be stronger than that of IDCs (Joensuu et al, 1994); these findings
also suggest that ILC is biologically less aggressive than IDC.
Patients with node-negative ILC and with a primary tumour size
2 cm or less (pTlNOMO) had a 100% 10-year survival rate in our
series, suggesting that small ILCs have as good a prognosis as
tubular, mucinous, papillary and cribriform carcinomas, which are
associated with a particularly favourable outcome. The finding that
node-negative ILCs with a SPF less than 4% have a 100% 20-year
survival rate also supports the view that there is a subgroup of ILC
that can be defined by the current methodology and that is associ-
ated with excellent long-term survival even if no adjuvant therapy
is given.
The presence of tumour necrosis was strongly associated with
poor prognosis in the current series. To our knowledge, the value
of tumour necrosis as a prognostic factor in ILC has not been
previously investigated. ILCs with necrotic areas had only a 16%
10-year survival rate compared with 72% in ILC without necrosis,
but the rarity ofthis feature (present only in < 10% ofcases) limits
its use as a prognostic factor.
We conclude that, in comparison to IDC:
1. ILC is associated with better short-term and long-term
survival;
2. the distribution of several established prognostic factors is
more favourable in ILC and they explain the better prognosis
ofILC;
3. in addition to the primary tumour size and axillary nodal
status, the presence of tumour necrosis and the cellular prolif-
eration rate are important prognostic features in ILC;
4. contralateral breast cancer is more commonly diagnosed in
patients with ILC;
5. the results suggest that there exist subgroups of ILC
(pTlNOMO or node-negative ILC with SPF < 4%) that carry
excellent long-term prognosis with the 20-year corrected
survival rate approaching 100% even iftreated without
adjuvant therapy.
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